Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Research & Development (2016 - 2025)

Historic Research & Development for Outlook Therapeutics (OTLK) over the last 7 years, with Q4 2025 value amounting to $3.6 million.

  • Outlook Therapeutics' Research & Development changed N/A to $3.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $21.2 million, marking a year-over-year change of. This contributed to the annual value of $27.2 million for FY2025, which is 3491.7% down from last year.
  • Outlook Therapeutics' Research & Development amounted to $3.6 million in Q4 2025.
  • Over the past 5 years, Outlook Therapeutics' Research & Development peaked at $7.1 million during Q2 2025, and registered a low of $3.6 million during Q4 2025.